{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T08:33:47Z","timestamp":1765355627819},"reference-count":36,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,2,28]],"date-time":"2012-02-28T00:00:00Z","timestamp":1330387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Histopathology"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:p>Li C, Li Y, Wang X, Wang Z, Cai J, Wang L, Zhao Y, Song H, Meng X, Ning X, Xu C, Lin M, Li L &amp; Geng J \u2028(2012) <jats:italic>Histopathology<\/jats:italic>\u00a0<jats:bold>60,<\/jats:bold> 953\u2013963<\/jats:p><jats:p><jats:bold>Elevated expression of astrocyte elevated gene\u20101 (AEG\u20101) is correlated with cisplatin\u2010based chemoresistance and shortened outcome in patients with stages III\u2013IV serous ovarian carcinoma<\/jats:bold><\/jats:p><jats:p><jats:bold>Aims:\u2002<\/jats:bold> To correlate astrocyte elevated gene\u20101 (AEG\u20101) expression with the clinicopathological features and outcome of patients with stages III\u2013IV ovarian serous carcinoma, and to clinically assess the involvement of AEG\u20101 in acquired cisplatin resistance.<\/jats:p><jats:p><jats:bold>Methods and results:\u2002<\/jats:bold> The frequency and intensity of immunohistochemical AEG\u20101 expression increased in a step\u2010wise fashion from normal to chemosensitive to chemoresistant tissues. These observations were confirmed by Western blot analysis. AEG\u20101 expression level was correlated with lymph nodal metastasis, histological differentiation, residual tumour size and response to primary chemotherapy. Five\u2010year progression\u2010free survival (PFS) and overall survival (OS) rates were lower in the high\u2010expression group than that in the low\u2010expression group. AEG\u20101 overexpression was an independent but poor prognostic factor in the OS and PFS of these patients, as determined by multivariate Cox regression analysis. Multivariate logistic regression analysis revealed that the presence of cisplatin\u2010based chemoresistance was significantly associated with expression level of AEG\u20101 and the degree of residual disease (<jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.0001 and <jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.0027, respectively).<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Our findings indicate that tumour AEG\u20101 overexpression is associated with poor prognosis and cisplatin resistance in advanced serous ovarian cancer.<\/jats:p>","DOI":"10.1111\/j.1365-2559.2012.04182.x","type":"journal-article","created":{"date-parts":[[2012,2,28]],"date-time":"2012-02-28T14:55:20Z","timestamp":1330440920000},"page":"953-963","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Elevated expression of astrocyte elevated gene\u20101 (AEG\u20101) is correlated with cisplatin\u2010based chemoresistance and shortened outcome in patients with stages III\u2013IV serous ovarian carcinoma"],"prefix":"10.1111","volume":"60","author":[{"given":"Cong","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongtao","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangning","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Ning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lejing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingshu","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,2,28]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20073"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(04)00002-9"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1098-2388(200007\/08)19:1<3::AID-SSU2>3.0.CO;2-S"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1248"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2002.01384.x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(04)00079-0"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2046"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.223"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205445"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2011.01.008"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.11.013"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2005.04.006"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210713"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0608386103"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210572"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI36460"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3029"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.01.010"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3838"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6164"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0910936106"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1846"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.171"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0049"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0752"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2010.02.007"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2010_06_522"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9475-6"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/IGC.0b013e3181ef8e21"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-010-1009-3"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21788"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7292(00)90001-8"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-58564-7"},{"key":"e_1_2_8_35_2","unstructured":"MorganRJ Jr AlvarezRD ArmstrongDKet\u00a0al.Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. NCCN clinical practice guidelines in oncology. v.2.2009."},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182145561"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.11.1.13835"}],"container-title":["Histopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2559.2012.04182.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2559.2012.04182.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T23:02:41Z","timestamp":1697324561000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2559.2012.04182.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,28]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1111\/j.1365-2559.2012.04182.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2559.2012.04182.x","archive":["Portico"],"relation":{},"ISSN":["0309-0167","1365-2559"],"issn-type":[{"value":"0309-0167","type":"print"},{"value":"1365-2559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,28]]},"assertion":[{"value":"2012-02-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}